Advantage Foundry
$20M Strategic Acquisition Proposal
The Field Experimentation Operating System that turns every Gilead field employee into a researcher. Voice-first evidence capture, palindromic learning, and SPINOR-RL allocation — built for pharma field execution.
The Problem
Gilead invests >50% of SG&A in sales reps and brand marketing. But field knowledge is lost, experiments are never run, and best practices stay trapped in individual reps.
>50%
of SG&A spent on field reps
Gilead internal acknowledgment
50%
of HCPs are fully accessible today
Gilead commercial leadership
$0
of field knowledge captured as structured evidence
Industry baseline
The Solution
Advantage Foundry is the missing layer in Gilead's commercial tech stack — structured field experimentation that complements Veeva Vault CRM and the Gilead-DnA platform.
Voice-First Evidence Capture
Reps speak their field observations. LLM extracts structured evidence — metrics, mechanisms, confounders. No forms. No typing. 18-state deterministic state machine with pharma compliance built-in.
SPINOR-RL Allocation Engine
10 mission classes (Scout, Field, Builder, Replication, Saboteur, Mutation, Translator, Recovery, Channel, Palindrome). RL-based allocation prevents fatigue and maximizes learning across the field force.
Palindromic Learning
Every discovered advantage travels forward into deployment, then backward through falsification, redistribution, and renewed research. Nothing becomes permanent merely because it worked once.
Anti-Gaming Controls
Pre-registered conditions, holdout testing, duplicate detection, selective reporting penalties. Activity ≠ effort ≠ evidence ≠ causality. Built for pharma compliance from day one.
Gilead Strategic Fit
Advantage Foundry fills the gap between Gilead's data infrastructure (Gilead-DnA) and CRM platform (Veeva Vault CRM) — the experimentation layer that neither provides.
Gilead-DnA
Data platform
Advantage Foundry
Experimentation layer
Veeva Vault CRM
CRM platform
Cognizant AI
AI services
Advantage Foundry sits between data and CRM — designing, running, and attributing field experiments that feed both systems.
Market Opportunity
The pharma field execution software market is $3.6B today, growing to $6B by 2033. No existing vendor provides structured field experimentation.
Sales Force Effectiveness
$3.6B
$6.0B by 2033
CAGR 7.5%
Commercial Analytics
$4.8B
$14.1B by 2035
CAGR 12.7%
AI Sales Enablement
$3.8B
$14.2B by 2034
CAGR 15.8%
Pharma CRM
$4.7B
$13.8B by 2034
CAGR 17.6%
Competitive Gap
Veeva / IQVIA / ZS
Provide recommendations and analytics. Don't design or run controlled experiments.
Advantage Foundry
Designs, runs, and attributes field experiments. Tests those recommendations before rollout.
Axtria / Tiger Analytics
Provide analytics infrastructure. Don't provide experimentation infrastructure.
The ROI Case
$20M acquisition pays back in <12 months through field force optimization across Gilead's 3,933 sales & marketing employees.
Revenue Retention
Cost Optimization
Total annual value
$28.3M/year
Payback period: 8.5 months on $20M acquisition
Technology & IP
Production-grade Next.js application with SQLite persistence, multi-tenant architecture, and 12+ LLM-powered API endpoints.
239
Source files
173
Passing tests
12+
API endpoints
9
LLM engines
10
Mission classes
18
Voice states
8
Palindrome stages
5
Evolution levels
Architecture
Deal Structure
$20M technology tuck-in acquisition. Comparable to Gilead's $35M Genesis Therapeutics collaboration — but for commercial operations instead of R&D.
Option A
Acquisition
$20M
Cash, technology + IP
Full technology transfer, source code, and integration support
Option B
Pilot-to-Acquire
$2M → $20M
6-month pilot, then acquisition
Paid pilot in one therapeutic area, acquisition triggered by proven ROI
Option C
Strategic Partnership
$5M + milestones
Lower upfront, milestone-based
Similar to Genesis model: upfront + contingent milestones
Alignment with Gilead Leadership
Johanna Mercier
Chief Commercial & Corporate Affairs Officer
Owns the field force that Advantage Foundry optimizes. Direct ROI accountability.
Anna Åsberg
Global CIO
Led Veeva Vault CRM decision. Advantage Foundry integrates natively with Veeva and Gilead-DnA.
Joydeep Ganguly
SVP Corporate Operations & Interim CIO
Manages Cognizant partnership. Advantage Foundry complements AI-driven commercial solutions.
Daniel O'Day
CEO
Pipeline quality 'never stronger'. Advantage Foundry optimizes launch execution for new assets.
Next Steps
Live Demo
Experience the voice-first evidence capture and SPINOR-RL dashboard with Gilead-specific data
Try Live DemoTechnical Review
Architecture walkthrough, security review, and integration planning with Gilead-DnA and Veeva teams
Pilot Proposal
6-month pilot in one therapeutic area (HIV or Oncology) with defined success metrics
Acquisition Terms
Structure and close the $20M acquisition with technology transfer and integration support